As you can see that JAGX is got a cup and handle formation for bullish continuation follow by a bullish pennant uptrend continuation. In addition JAGX halted 3 times Last Friday 01/15/2021
Review Below
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 12:07 PM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 12:07 PM
Jan 14 · Reuters
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 12:01 PM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 12:01 PM
Jan 14 · Reuters
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 11:56 AM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 11:56 AM
The meeting will go over plans for Napo EU, a company expected to become a subsidiary of Jaguar Health in Italy, to merge with a SPAC. The meeting will be presented by SPAC sponsor Andreea Porcelli and Jaguar Health president and CEO Lisa Conte.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals.
Review Below
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 12:07 PM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 12:07 PM
Jan 14 · Reuters
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 12:01 PM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 12:01 PM
Jan 14 · Reuters
NASDAQ TRADE HALT JAGX.O VOLATILITY TRADING PAUSE AT 11:56 AM
NASDAQ TRADE HALT NASDAQ:JAGX VOLATILITY TRADING PAUSE AT 11:56 AM
The meeting will go over plans for Napo EU, a company expected to become a subsidiary of Jaguar Health in Italy, to merge with a SPAC. The meeting will be presented by SPAC sponsor Andreea Porcelli and Jaguar Health president and CEO Lisa Conte.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals.
Comment:
*01/14/21